The growth of the recombinant plasma proteins therapeutics market is propelled by the increasing prevalence of chronic diseases and a vulnerable adult population. Additionally, the high prevalence rate of hematological disorders, where recombinant plasma therapy is a dominant treatment, and the rapid adoption of recombinant biotechnology for coagulation production are key drivers. These factors collectively contribute to the expansion of the recombinant plasma proteins therapeutics market, fostering its growth and market potential.
According to Data Bridge Market Research, the Recombinant Plasma Proteins Therapeutics Market is expected to grow with a CAGR of 5.10% in the forecast period of 2022 to 2029.
“Technological advancements surging market’s growth”
Technological advancements are playing a pivotal role in fuelling the growth of the Global recombinant plasma proteins therapeutics market. Innovations such as recombinant DNA technology and protein engineering have enabled the production of highly effective and targeted therapeutic proteins derived from plasma. These advancements have enhanced the efficiency, safety, and scalability of production processes, leading to the development of novel therapies and expanded treatment options for various diseases. The continuous progress in technology is expected to further propel the growth of this market in the future.
What restraints the growth of the recombinant plasma proteins therapeutics market?
“High price of recombinant plasma proteins therapeutics”
The growth of the global recombinant plasma proteins therapeutics market is hindered by stringent regulations. Regulatory authorities impose rigorous requirements and compliance standards to ensure the safety, efficacy, and quality of therapeutic products derived from plasma proteins. These regulations often involve extensive clinical trials, lengthy approval processes, and stringent manufacturing practices. While these regulations are necessary to protect patient safety, they can increase the time and cost associated with bringing new therapies to market, thereby restraining the growth of the market.
Segmentation: Recombinant Plasma Proteins Therapeutics Market
The recombinant plasma proteins therapeutics market is segmented on the basis of drug class, cell line, indication, route of administration and end users.
- On the basis of drug class, the recombinant plasma proteins therapeutics market has been segmented into recombinant coagulation factors, human c1 esterase inhibitor.
- On the basis of cell line, the recombinant plasma proteins therapeutics market has been segmented into chinese hamster ovary (CHO) cells , baby hamster kidney (BHK) cell line, human embryonic kidney (HEK) cell line, others.
- On the basis of indication, the recombinant plasma proteins therapeutics market has been segmented into hemophilia A, hemophilia B, von willebrand disease, others.
- On the basis of route of administration, the recombinant plasma proteins therapeutics market has been segmented into intramuscular, subcutaneous, and intravenous.
- On the basis of end users, the recombinant plasma proteins therapeutics market has been segmented into hospitals, specialty clinics, others.
Regional Insights: North America dominates the Recombinant Plasma Proteins Therapeutics Market
North America dominates the recombinant plasma proteins therapeutics market due to the high prevalence rate of hemophilia in the region and the increasing adoption of recombinant therapies.
Europe is expected to grow during the forecast period of 2022-2029 due to the presence and dedication of established market players like Novo Nordisk and Bayer AG in the region contribute to the prominence of the industry.
To know more about the study visit, https://www.databridgemarketresearch.com/jp/reports/global-recombinant-plasma-proteins-therapeutics-market
The Prominent Key Players Operating in the Recombinant Plasma Proteins Therapeutics Market Include:
- Ferring B.V. (Netherlands)
- CSL Limited (Australia)
- Takeda Pharmaceutical Company Limited (Japan)
- Pfizer Inc. (U.S.)
- Bayer AG (Germany)
- Baxter (U.S.)
- Novo Nordisk A/S (Denmark)
- HEMA Biologics, LLC (U.S.)
- OPKO Health, Inc. (U.S.)
- Octapharma (Switzerland)
- Sinocelltech Ltd (China)
- CELGENE CORPORATION (U.S.)
- Bionor Holding AS (Norway)
- CELLECTAR BIOSCIENCES, INC. (U.S.)
- eFFECTOR Therapeutics, Inc. (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Bristol-Myers Squibb Company (U.S.)
- Abbott (U.S.)
- Medtronic (U.S.)
- BD (U.S.)
- Cook (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
Above are the key players covered in the report, to know about more and exhaustive list of recombinant plasma proteins therapeutics market companies contact, https://www.databridgemarketresearch.com/jp/contact
Research Methodology: Global Recombinant Plasma Proteins Therapeutics Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
